Patents by Inventor Gabrielle R. Kolakowski

Gabrielle R. Kolakowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RET kinase inhibitors
    Patent number: 11970485
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: April 30, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
  • Fused heterocyclic compounds as RET kinase inhibitors
    Patent number: 11964988
    Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: April 23, 2024
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Dean Kahn, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L McKenney, Andrew T. Metcalf, David A. Moreno, Brett Prigaro, Ginelle A. Ramann, Li Ren, Shane M. Walls, Hailong Zhang
  • Compounds useful for inhibiting RET kinase
    Patent number: 11964968
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: April 23, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Erin D. Anderson, Steven W. Andrews, Kevin R. Condroski, Thomas C. Irvin, Gabrielle R. Kolakowski, Manoj Kumar, Elizabeth A. McFaddin, Megan McKenney, Michael J. Munchhof, Michael B. Welch
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20240066029
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: June 27, 2023
    Publication date: February 29, 2024
    Inventors: Steven W. ANDREWS, Sean ARONOW, James F. Blake, Barbara J. BRANDHUBER, Adam COOK, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Oren T. MCNULTY, Andrew T. METCALF, David A. MORENO, Tony P. TANG, Li REN
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20240051948
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: October 13, 2023
    Publication date: February 15, 2024
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Alfredo PICADO, Gerit Maria POTOTSCHNIG, Michael Brian WELCH, Tien WIDJAJA, Xiaohong CHEN, Nathan Edward WRIGHT, Hua-Yu WANG
  • Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
    Patent number: 11878970
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 26, 2022
    Date of Patent: January 23, 2024
    Assignee: PETRA PHARMA CORPORATION
    Inventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Xiaohong Chen, Surendra Dawadi, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Gabrielle R. Kolakowski, Jennifer Lynn Knight, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, Johnathan Alexander McLean, Gerit Maria Pototschnig, Hua-Yu Wang, Michael Brian Welch, Tien Widjaja
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20240018115
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 28, 2023
    Publication date: January 18, 2024
    Inventors: Sean Douglas ARONOW, Carina Ivonne JETTE, Gabrielle R. KOLAKOWSKI, Christopher Glenn MAYNE, Hua-Yu WANG, Michael Brian WELCH, Nathan Edward WRIGHT, Gerit Maria POTOTSCHNIG, Warren Christopher CHAN, Surendra DAWADI, Manoj KUMAR, Katelyn Frances LONG, Alfredo PICADO, Marcos Adrian SAINZ, Tarek SAMMAKIA, LaToya Denise SCAGGS, Zhicheng SUN, Erin Danielle ANDERSON, Shuai CHEN, Thomas Combs IRVIN, Edward A. KESICKI, Xia WANG, Ganesh Mangalsing MURHADE
  • Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
    Patent number: 11873295
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: January 16, 2024
    Assignee: PETRA PHARMA CORPORATION
    Inventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Surendra Dawadi, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Gabrielle R. Kolakowski, Jennifer Lynn Knight, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, Alfredo Picado, Gerit Maria Pototschnig, Michael Brian Welch, Tien Widjaja, Xiaohong Chen, Nathan Edward Wright, Hua-Yu Wang
  • Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
    Patent number: 11851434
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: December 26, 2023
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, David A. Moreno, Li Ren, Shane M. Walls
  • Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
    Patent number: 11807651
    Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: November 7, 2023
    Assignees: Loxo Oncology Inc., Array BioPharma Inc.
    Inventors: Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
  • COMPOUNDS USEFUL FOR INHIBITING RET KINASE
    Publication number: 20230312544
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Application
    Filed: February 6, 2023
    Publication date: October 5, 2023
    Inventors: Erin D. ANDERSON, Steven W. ANDREWS, Kevin R. CONDROSKI, Thomas C. IRVIN, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan MCKENNEY, Michael J. MUNCHHOF, Michael B. WELCH
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20230286960
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Application
    Filed: April 18, 2023
    Publication date: September 14, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Markus K. DAHLGREN, Shulu FENG, Aleksey I. GERASYUTO, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Anke KLIPPEL-GIESE, Jennifer Lynn KNIGHT, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, David L. MCELLIGOTT, Johnathan Alexander MCLEAN, Loredana PUCA, Kannan Karukurichi RAVI, Daniel Lee SEVERANCE, Michael Brian WELCH, Tien WIDJAJA
  • RET KINASE INHIBITORS
    Publication number: 20230265085
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Application
    Filed: October 19, 2022
    Publication date: August 24, 2023
    Inventors: Gabrielle R. KOLAKOWSKI, Erin D. ANDERSON, Steven W. ANDREWS, Christopher Pierre Albert Jean BOLDRON, Kevin R. CONDROSKI, Thomas C. IRVIN, Manoj KUMAR, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Johnathan Alexander MCLEAN, Tiphaine MOURET, Michael J. MUNCHHOF, Thomas Pierre Dino PANCALDI, Michael Alexander PILKINGTON-MIKSA, Marta PINTO
  • RET kinase inhibitors
    Patent number: 11697647
    Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: July 11, 2023
    Assignee: Eli Lilly and Company
    Inventors: Gabrielle R. Kolakowski, Erin D. Anderson, Steven W. Andrews, Christopher Pierre Albert Jean Boldron, Kevin R. Condroski, Thomas C. Irvin, Manoj Kumar, Elizabeth A. McFaddin, Megan L. McKenney, Johnathan Alexander McLean, Tiphaine Mouret, Michael J. Munchhof, Thomas Pierre Dino Pancaldi, Michael Alexander Pilkington-Miksa, Marta Pinto
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 11648243
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 16, 2023
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, James Collier, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. Mcfaddin, Megan L. Mckenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Ginelle A. Ramann, Tony P. Tang, Li Ren, Shane M. Walls
  • Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
    Patent number: 11649227
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: May 16, 2023
    Assignee: Petra Pharma Corporation
    Inventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Markus K. Dahlgren, Shulu Feng, Aleksey I. Gerasyuto, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Anke Klippel-Giese, Jennifer Lynn Knight, Gabrielle R. Kolakowski, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, David L. McElligott, Johnathan Alexander McLean, Loredana Puca, Kannan Karukurichi Ravi, Daniel Lee Severance, Michael Brian Welch, Tien Widjaja
  • ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE
    Publication number: 20230096175
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 26, 2022
    Publication date: March 30, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Xiaohong CHEN, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Johnathan Alexander MCLEAN, Gerit Maria POTOTSCHNIG, Hua-Yu WANG, Michael Brian WELCH, Tien WIDJAJA
  • Compounds useful for inhibiting RET kinase
    Patent number: 11613533
    Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: March 28, 2023
    Assignee: Eli Lilly and Company
    Inventors: Erin D. Anderson, Steven W. Andrews, Kevin R. Condroski, Thomas C. Irvin, Gabrielle R. Kolakowski, Manoj Kumar, Elizabeth A. McFaddin, Megan McKenney, Michael J. Munchhof, Michael B. Welch
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20230090520
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 23, 2023
    Inventors: Steven W. ANDREWS, Sean ARONOW, James F. BLAKE, Barbara J. BRANDHUBER, Adam COOK, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Oren T. MCNULTY, Andrew T. METCALF, David A. MORENO, Tony P. TANG, Li REN
  • Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
    Patent number: 11603374
    Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 14, 2023
    Assignee: Array BioPharma Inc.
    Inventors: James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Andrew T. Metcalf, David A. Moreno, Brett Prigaro, Ginelle A. Ramann, Li Ren